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Abstract
Background: The pro-nociceptive kinin B1 receptor (B1R) is upregulated on sensory C-fibres, astrocytes and microglia 
in the spinal cord of streptozotocin (STZ)-diabetic rat. This study aims at defining the role of microglial kinin B1R in 
diabetic pain neuropathy.
Methods: Sprague-Dawley rats were made diabetic with STZ (65 mg/kg, i.p.), and 4 days later, two specific inhibitors of 
microglial cells (fluorocitrate, 1 nmol, i.t.; minocycline, 10 mg/kg, i.p.) were administered to assess the impact on 
thermal hyperalgesia, allodynia and mRNA expression (qRT-PCR) of B1R and pro-inflammatory markers. Spinal B1R 
binding sites ((125I)-HPP-desArg10-Hoe 140) were also measured by quantitative autoradiography. Inhibition of 
microglia was confirmed by confocal microscopy with the specific marker Iba-1. Effects of intrathecal and/or systemic 
administration of B1R agonist (des-Arg9-BK) and antagonists (SSR240612 and R-715) were measured on neuropathic 
pain manifestations.
Results: STZ-diabetic rats displayed significant tactile and cold allodynia compared with control rats. Intrathecal or 
peripheral blockade of B1R or inhibition of microglia reversed time-dependently tactile and cold allodynia in diabetic 
rats without affecting basal values in control rats. Microglia inhibition also abolished thermal hyperalgesia and the 
enhanced allodynia induced by intrathecal des-Arg9-BK without affecting hyperglycemia in STZ rats. The enhanced 
mRNA expression (B1R, IL-1β, TNF-α, TRPV1) and Iba-1 immunoreactivity in the STZ spinal cord were normalized by 
fluorocitrate or minocycline, yet B1R binding sites were reduced by 38%.
Conclusion: The upregulation of kinin B1R in spinal dorsal horn microglia by pro-inflammatory cytokines is proposed 
as a crucial mechanism in early pain neuropathy in STZ-diabetic rats.
Background
According to the World Health Organization, over 300
millions of people worldwide will be diagnosed with dia-
betes mellitus by the year 2025. Diabetes leads to micro-
and macro-vascular complications such as hypertension,
retinopathy, nephropathy, sensory and autonomic poly-
neuropathies [1]. Patients with diabetic sensory neuropa-
thy experience a variety of aberrant sensations including
spontaneous pain, hyperalgesia and hypersensitivity to
non-painful stimuli, which is commonly known as allo-
dynia [2,3]. Epidemiological data demonstrated that
peripheral diabetic polyneuropathy affects 50-60% of dia-
betic patients and nowadays is recognized as the most
difficult pain to treat since it is largely resistant to com-
mercially available treatments [3-5]. The lack of knowl-
edge regarding the exact mechanism leading to diabetes-
induced neuropathic pain put emphasis on the need to
identify cellular and molecular targets to develop new
therapeutic approaches.
Recent studies highlighted a primary role for the induc-
ible kinin B1 receptor (B1R) in mediation of nociception
and diabetes-induced neuropathic pain [6,7]. Kinins are
defined as pro-inflammatory and vasoactive peptides,
which act through the activation of two G-protein-cou-
pled receptors (R) denoted as B1 and B2 [8,9]. The B2R is
widely and constitutively expressed in central and periph-
eral tissues and is activated by its preferential agonists
bradykinin (BK) and Lys-BK. The B1R is activated by the
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active metabolites des-Arg9-BK and Lys-des-Arg9-BK and
has a low level of expression in healthy tissues [10]. The
latter receptor is upregulated after exposure to pro-
inflammatory cytokines, bacterial endotoxins, hypergly-
cemia-induced oxidative stress and diabetes [11-13]. B1R
knockout mice are less sensitive to pro-inflammatory
pain stimuli, spinal sensitization and diabetic hyperalge-
sia [14,15]. Pharmacological studies support a role for
B1R in mechanical and/or thermal hyperalgesia induced
by cytokines [16], formalin [17] and in neuropathic pain
induced by peripheral nerve injury [18] or as conse-
quence of type 1 and 2 diabetes mellitus [15,19-21]. Auto-
radiography studies showed a widespread distribution of
kinin B1R binding sites in the spinal cord of diabetic rats
[19,21-23]. This is consistent with the presence of B1R on
neuronal and non-neuronal elements, including sensory
C-fibres, astrocytes and microglia as revealed by confocal
microscopy in the spinal cord of streptozotocin (STZ)-
diabetic rats [22].
Microglia, known as macrophages of the central ner-
vous system (CNS), have for primary function to phago-
cyte debris and other pathogens in the CNS [24].
Nevertheless, emerging evidence suggests an important
role played by spinal microglial cells in STZ-induced pain
neuropathy. For instance, microglial activation and the
g e n e r a t i o n  o f  n e u r o p a t h i e s  i n  S T Z - d i a b e t i c  r a t s  w e r e
both prevented by Gabapentin treatment [25]. Moreover,
spinal microglial cells are upregulated in neuropathic
pain models of nerve injury [26,27]. Dorsal horn micro-
glia activation is thought to play a pivotal role in diabetes-
induced neuropathy via a MAPKp38α signaling pathway,
which was found essential for cytokines synthesis and
release [28,29].
The present study aimed at defining the role played by
spinal dorsal horn microglial kinin B1R in a classical rat
model of diabetes-induced pain neuropathy by using two
inhibitors of microglial cells. Formally, were tested flu-
orocitrate, a specific inhibitor of microglia Krebs cycle
[30], and minocycline, a broad spectrum tetracycline
antibiotic, which inhibits microglia activity by preventing
the translocation of the transcriptional nuclear factor
kappa B (NF-κB) to its nuclear promoter [31]. The spe-
cific objectives were to: 1) determine whether microglia
inhibitors can prevent thermal hyperalgesia and tactile
allodynia induced by spinal activation of B1R with the
selective agonist des-Arg9-BK in STZ-diabetic rats; 2)
compare the acute inhibition of B1R and microglial func-
tion on tactile and cold allodynia; 3) determine the effect
of microglia inhibition on the expression of B1R and pro-
inflammatory markers (IL-1β, TNF-α, TRPV1) by real-
time RT-PCR; 4) correlate changes of B1R mRNA levels
with those of B1R binding sites by quantitative autora-
diography; 5) measure the immunoreactivity of Iba-1 as
marker of microglia. This study was carried out in the
early phase of diabetes (4 days post-STZ) when allodynia,
spinal kinin B1R up-regulation and thermal hyperalgesia
upon intrathecal injection of des-Arg9-BK were found to
occur [7,23].
Methods
Animals and treatments
All research procedures and the care of the animals were
in compliance with the guiding principles for animal
experimentation as enunciated by the Canadian Council
on Animal Care and were approved by the Animal Care
Committee of our University. Male Sprague-Dawley rats
(225-250 g, Charles River, St-Constant, Que, Canada)
were housed two per cage, under controlled conditions of
temperature (23°C) and humidity (50%), on a 12 h light-
dark cycle and allowed free access to normal chow diet
(Charles River Rodent) and tap water.
Intrathecal implantation of catheter
Four days after arrival, rats were chronically implanted,
under isoflurane anaesthesia, with an indwelling intrathe-
cal (i.t.) polyethylene catheter (PE-10; Intramedic, Clay
Adams, NJ, USA) at the vertebral mid-lumbar level (L2 to
L4) through an incision made in the dura at the atlanto-
occipital junction [7]. This catheter was used for intrathe-
cal drug injections. On the day of surgery and for the 2
subsequent days, rats received antibiotics trimethoprim
and sulphadiazine (Tribrissen 24%, 30 mg/kg, s.c., Scher-
ing Canada Inc., Pointe Claire, Que, Canada) and the
analgesic ketoprofen (Anafen, 5 mg/kg, s.c., Merial Can-
ada Inc., Baie d'Urfé, Que, Canada).
STZ treatment
Five days after intrathecal implantation, rats were
injected under a low light condition with freshly prepared
STZ (65 mg/kg, i.p.; Zanosar, McKesson, Montreal, Que,
Canada). Age-matched controls were injected with vehi-
cle (sterile saline 0.9%, pH. 7.0). Blood glucose was mea-
sured with a commercial blood glucose-monitoring kit
(Accusoft; Roche Diagnostics, Laval, Que, Canada) from
a drop of blood obtained from the tail vein, in non-fasting
animals. Only STZ-treated rats whose blood glucose con-
centration was higher than 20 mM at day 4 were used and
considered as diabetic.
Tactile allodynia
Four days after STZ treatment, tactile allodynia was
assessed by measuring the hindpaw withdrawal threshold
to the application of a calibrated series of 6 von Frey fila-
ments (bending forces of 2, 4, 6, 8, 10 and 15 g) (Stoelting,
Wood Dale, IL, USA) using a modification of the up-
down method [32]. Starting with the filament that has theTalbot et al. Journal of Neuroinflammation 2010, 7:36
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lowest force (2 g), the filament was applied perpendicu-
larly to the mid-plantar surface with sufficient force to
cause the filament to buckle slightly. Brisk withdrawal or
paw flinching was considered as the positive response.
Each filament was applied five times to each paw (for 6-8
s per stimulation, with an inter stimulus interval of 1-2
min). Minimum recording of 5 positive responses (50%)
out of 10 stimulations for both paws was considered to be
the threshold (in grams). Absence of a response (less than
5 withdrawals) prompted use of the next graded filament
of increasing weight. The cut-off of a 15 g filament was
selected as the upper limit for testing, since stiffer fila-
ments tended to raise the entire limb rather than to
buckle, substantially changing the nature of the stimulus.
Control rat withdrawal threshold was between 10 and 12
g.
Cold allodynia
Four days after STZ treatment, cold allodynia was
assessed using the acetone drop method [33]. An acetone
bubble formed at the end of a standard plastic syringe
was placed to the plantar surface of the hindpaws. Ace-
tone was applied five times to each paw at intervals of 3-5
min. Control rats either ignored the stimulus or occa-
sionally responded with a small and brief withdrawal.
Allodynic rats responded with prompt and intense paw
withdrawal or escape behaviour to acetone application.
The frequency of paw withdrawal was expressed as a per-
centage (the number of paw withdrawals ÷ number of tri-
als × 100).
Tail-flick test
Intrathecally implanted rats were housed permanently in
the testing laboratory under continuous light to prevent
the endogenous release of opoids which could alter the
nociceptive threshold [34]. Testing began four days after
STZ treatment by placing awake rats in a plastic restrain-
ing box. The nociceptive threshold was taken as the reac-
tion time to remove the tail from above a source of
noxious radiant heat. The intensity of the heat stimulus
was set to elicit a tail-flick within 8-10 s. A 25 s cut-off
time was used to prevent tissue damage. Four groups of
rats (control, STZ-vehicle, STZ-fluorocitrate and STZ-
minocycline, n = 5) were tested for a maximum of three
consecutive days and euthanized with CO2  inhalation
after the last test. Fluorocitrate (1 nmol, i.t.) or minocy-
cline (10 mg/kg, i.p.) was administered 3 h prior to the
tail- flick test protocol. During the first two days, rats
received only 20 μl of artificial cerebrospinal fluid (aCSF)
as training experiments and to ensure that the intrathecal
catheter is patent. On the following day, each testing trial
lasted 1 h and consisted of 13 measurements of tail-flick
latency, spaced by 5 min intervals. The initial three mea-
surements were used to determine baseline latency. One
minute prior to the 4th reading (t = 15 min) the vehicle
(aCSF) was intrathecally injected. Fifteen min later, the
tested B1R agonist (des-Arg9-BK, 9.6 nmol or 10 μg) was
injected through the same route (t = 30 min) and its effect
on the tail-flick latency was measured 1 min later and on
three subsequent readings. Then substance P (6.6 nmol
or 10 μg) was injected intrathecally to assess the specific-
ity of B1R blockade on microglia.
Spinal cord preparation
For autoradiography, 4-day STZ-diabetic rats (without
intrathecal catheter) were anesthetised with CO2 inhala-
tion and then decapitated. Thoracic spinal cord (T3-T7)
was removed and frozen in 2-methylbutane (cooled at -
40°C following exposure to liquid nitrogen) and stored at
-80°C. For microscopy, rats were anesthetized with
sodium pentobarbital (80 mg/kg, i.p.) and perfused tran-
scardially with 0.1 M PBS (pH 7.4) (300 ml in 3 min), fol-
lowed by 4% paraformaldehyde in PBS (500 ml in 5 min).
The thoracic spinal cord (T3-T7) was removed and post-
fixed by immersion in paraformaldehyde (60 min at 4°C)
and washed in PBS [35]. Few days later, spinal cord seg-
ments were mounted in a gelatin block and serially cut
into 20-μm thick coronal sections with a cryostat. Sec-
tions were then thaw-mounted on Fisherbrand Super-
frost disposable microscope slides (Fisher Scientific, ON,
Canada) and kept at -80°C for 1 month to allow the adhe-
sion of sections to the coverslip glasses.
Quantitative autoradiography
The radioligand for kinin B1R, HPP-desArg10-
Hoe140 (3-(4 hydroxyphenyl) propionyl-desArg9-D-
Arg0(Hyp3,Thi5,D-Tic7,Oic8)Bradykinin) was synthesized
at the National Research Council of Canada (NRC, Mon-
treal, Que, Canada) and iodinated by the chloramine T
method [36]. Quantitative in vitro autoradiography was
conducted as described previously [23]. Briefly, sections
were incubated at room temperature for 90 min in 25
mM PIPES-NH4OH buffer (pH 7.4) containing: 1 mM
1,10-phenanthroline, 1 mM dithiothreitol, 0.014% baci-
tracin, 0.1 mM captopril, 0.2% bovine serum albumin
(protease free) and 7.5 mM magnesium chloride in the
presence of 200 pM of (125I)-HPP-desArg10-Hoe 140 (spe-
cific activity: 2000 cpm/fmol or 1212 Ci/mmol). Non-
specific binding was determined in the presence of 1 μM
of unlabeled B1R antagonist: R-715 (AcLys(D-
βNal7,Ile8)des-Arg9-BK) [8]. At the end of the incubation
period, slides were transferred sequentially through four
rinses of 4 min each in 25 mM PIPES (pH 7.4; 4°C)
dipped for 15 s in distilled water (4°C) to remove the
excess of salts, and then air-dried. Kodak Scientific Imag-
ing Films BIOMAX ™ MR® (Amersham Pharmacia Bio-
tech Canada) were juxtaposed onto the slides in theTalbot et al. Journal of Neuroinflammation 2010, 7:36
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presence of (125I)-microscales and exposed at room tem-
perature for 6 days. The films were developed (GBX
developer) and fixed (GBX fixer). Autoradiograms were
quantified by densitometry using an MCID™ image analy-
sis system (Imaging Research, St. Catharines, ON, Can-
ada). A standard curve from (125I)-microscales were used
to convert density levels into fentomoles per milligram of
proteins [37]. Specific binding was determined by sub-
tracting values of nonspecific binding from that of total
binding.
Confocal microscopy
On the day of experiments, slides of spinal cords were
briefly (10 min) thawed at room temperature (RT) to
enhance sections adhesion. Then, sections were washed
for 10 min in 0.1 M PBS buffer (pH 7.4) and incubated for
30 min (RT) in blocking buffer (PBS containing 3% bovine
serum albumin, 3% donkey serum and 0.5% triton X-100)
to prevent non-specific labeling. Sections were incubated
2 h (RT) with the blocking buffer containing 2 μg/ml of
the primary antibody rabbit anti-Ionized calcium binding
adapter molecule-1 (anti-Iba-1, Wako, Richmond, VA, USA)
[22]. Sections were washed 3 times (5 min) and incubated
90 min (RT) with PBS containing 1:500 of the secondary
antibody rhodamine anti-rabbit (ext: 550 nm; em: 570
nm) (Chemicon, Hornby, ON, Canada). Slides were
washed 3 times (5 min), mounted with coverslip, fixed
with Vectashield (Vector Laboratories, Burlington, ON,
Canada) 12 h (RT) and stored at -4°C for up to 1 month.
The examination was limited to the dorsal horn under
confocal microscope (Leica Confocal microscope, Rich-
mond Hill, ON, Canada), using the krypton laser (568 nm).
Quantification of Iba-1 immunolabelling
Leica confocal program was used to quantify the mean
pixel energy of Iba-1 in the spinal dorsal horn. A mini-
mum of 4 slides from 4 different rats were measured. In
everyone slide, relative background energy was sub-
tracted from the mean pixel energy.
SYBR green-based quantitative RT-PCR
Four days after injection of STZ, rats were anesthetised
with CO2 inhalation and then decapitated. The upper
thoracic spinal cord (T1-T2) was isolated and approxi-
mately 10 mg of tissue were put in RNAlater stabilization
reagent (QIAGEN, Valencia, CA, USA). Total RNA was
extracted from tissue according to the manufacturer's
instructions. First-strand cDNA synthesized from 400 ng
total RNA with random hexamer primers was used as the
template for each reaction with the QuantiTect Rev Tran-
scription Kit (QIAGEN). SYBR Green-based real-time
quantitative PCR using Mx3000 p device for signal detec-
tion (Stratagene, La Jolla, CA, USA) was performed as
described [22]. PCR was performed in SYBR Green Mas-
ter mix (QIAGEN) with 300 nM of each primer. For stan-
dardization and quantification, rat 18S was amplified
simultaneously. The primer pairs were designed by Vec-
tor NTI software (Table 1). PCR conditions were as fol-
lows: 95°C for 15 min, followed by 46 cycles at 94°C for 15
s, 60°C for 30 s and 72°C for 30 s. The cycle threshold (Ct)
value represents the cycle number at which a fluorescent
signal rises statistically above background. The relative
quantification of gene expression was analyzed by the 2-
ΔΔCt method [38].
Table 1: PCR primer pairs used in this study
Sequences Position Gen Bank
18S forward 5' TCA ACT TTC GAT GGT AGT CGC CGT 3' 363 - 386 X01117
18S reverse 5' TCC TTG GAT GTG GTA GCC GTT TCT 3' 470 - 447
B1 receptor forward 5' GCA GCG CTT AAC CAT AGC GGA AAT 3' 367 - 391 NM_030851
B1 receptor reverse 5' CCA GTT GAA ACG GTT CCC GAT GTT 3' 478 - 454
IL-1β forward 5' TGT CAC TCA TTG TGG CTG TGG AGA 3' 247 - 270 NM_031512
IL-1β reverse 5' TGG GAA CAT CAC ACA CTA GCA GGT 3' 411 - 388
TNF-α forward 5' ATG ATC CGA GAT GTG GAA CTG GCA 3' 160 - 183 NM_012675
TNF-α reverse 5' AAT GAG AAG AGG CTG AGG CAC AGA 3' 257 - 234
TRPV1 forward 5' GCA CAA TGG GCA GAA TGA CAC CAT 3' 575 - 598 NM_031982
TRPV1 reverse 5' GGC ATT GAC AAA CTG CTT CAG GCT 3' 656 - 633Talbot et al. Journal of Neuroinflammation 2010, 7:36
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Drugs
The kinin B1R was blocked with the orally active, non-
peptide B1R antagonist, SSR240612, which crosses readily
the blood-brain barrier [39]. It was kindly provided by
Sanofi-Aventis R&D (Montpellier, France). R-715 was
also used as B1R antagonist as it does not cross the blood-
brain barrier due to its peptide nature [8]. It was gener-
ously obtained from Dr Fernand Gobeil Jr. (Pharmacol-
ogy, Sherbrooke University, Sherbrooke, Que, Canada).
SSR240612 (10 mg/kg) was administered by gavage (vol-
ume of 1 ml by 100 g of rat body weight) while R-715 (10
mg/kg) was given intraperitoneally. Both antagonists at
this dose blocked allodynia in a rat model of type 2 diabe-
tes [20,21]. SSR240612 and R-715 were also administered
intrathecally at a single dose of 10 μg to better dissociate
the spinal and peripheral contribution of B1R in the func-
tional tests. Microglial cells were blocked with fluoroci-
trate (1 nmol, i.t.), a selective inhibitor of the Krebs cycle
enzyme aconitase [40,41] and with minocycline (10 mg/
kg, i.p.), an antibiotic preventing the translocation of
microglia NF-κB to its nuclear promoter [31]. The B1R
agonist, des-Arg9-BK (9.6 nmol, i.t.) caused hyperalgesia
in the tail-flick test in STZ rats [7] while the NK-1 recep-
tor agonist, substance P (SP) (6.6 nmol, i.t.) caused hyper-
algesia in the tail-flick test i n  c o n t r o l  r a t s  [ 4 2 ] .  B o t h
agonists were purchased from Bachem Bioscience Inc.
(King of Prussia, PA, USA). For intraperitoneal injections,
minocycline and R-715 were dissolved in 0.9% sterile
saline. For intrathecal injections, des-Arg9-BK, SP, R-715
and fluorocitrate were dissolved in aCSF. For all treat-
ments, SSR240612 was dissolved in dimethylsulphoxide
(0.5%), and then ethanol (5%) and Tween-80 (5%) were
added in this sequence [20]. The solution was completed
in distilled water. Fluorocitrate, minocycline and all other
reagents were purchased from Sigma-Aldrich Canada,
Ltd (Oakville, ON, Canada).
Statistical analysis
All data were expressed as the means ± S.E.M. obtained
from n rats. In the tail-flick test, data were calculated as a
percentage of the maximum possible effect (% MPE)
according to the following formula: % MPE = 100 × (drug
latency minus baseline latency) ÷ (cut-off time minus
baseline latency) [7]. The baseline latency corresponds to
the average of the first three measurements. Statistical
significance was determined with Student's t-test for
paired samples or one-way analysis of variance (ANOVA)
followed by post-hoc Bonferonni test for multiple com-
parisons. Data for allodynia were analysed with the non-
parametric Kruskal-Wallis post-test. Only probability (P)
values less than 0.05 were considered to be statistically
significant.
Results
Influence of microglia inhibitors and B1R antagonists on 
STZ-induced hyperglycemia
As depicted in Figure 1, rats which received STZ (65 mg/
kg, i.p.) 4 days earlier displayed a significant increase of
blood glucose concentration compared with vehicle-
matched control rats. Blood glucose levels in control and
STZ-treated rats were not affected by fluorocitrate (1
nmol, i.t.) or minocycline (10 mg/kg, i.p.) injected 3 h ear-
lier (Figure 1). SSR240612 (10 mg/kg, p.o.) reduced signif-
icantly hyperglycemia in STZ-treated rats at 3 h post-
gavage; the inhibitory effect of the B1R antagonist was not
significant at 6 h and was completely resolved at 24 h. A
similar pattern of anti-hyperglycemia was seen with R-
715 (10 mg/kg, i.p.), yet the inhibitory effect did not reach
statistical significance (Figure 2-A). Either antagonist did
not affect glycemia in control rats. Intrathecally adminis-
tered R-715 and SSR240612 (10 μg) failed to alter blood
glucose levels in both control and STZ-diabetic rats (Fig-
ure 2-B).
Effect of microglia inhibitors on Iba-1 microglial 
immunoreactivity
A quantitative immunolabelling with a specific immuno-
marker of microglia Iba-1 was employed to validate the
use of minocycline and fluorocitrate as inhibitors of
microglia activity. As shown in Figure 3-A, immunoreac-
tivity to Iba-1 was much more striking in the spinal dorsal
horn of STZ-diabetic rats than in matched control spinal
dorsal horn. Immunoreactive microglial cells in STZ spi-
Figure 1 Effect of microglia inhibitors administered 3 h earlier on 
blood glucose concentration in control and 4-day STZ-diabetic 
rats. Data are the mean ± S.E.M. of 5 rats in each group. Statistical com-
parison to control rats is indicated by ***P < 0.001.Talbot et al. Journal of Neuroinflammation 2010, 7:36
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nal cord were more numerous, thicker and displayed
higher mean pixel energy than microglia of control spinal
dorsal horn. Importantly, treatment with fluorocitrate or
minocycline reversed and normalized the enhanced Iba-1
immunoreactivity in STZ spinal cord microglia (Figure 3-
B). The same treatment with fluorocitrate or minocycline
had no effect on the mean pixel energy of Iba-1 in control
spinal dorsal horn.
Effect of microglia inhibitors on mRNA levels of B1R, TRPV1, 
IL-1β and TNF-α in STZ thoracic spinal cord
Since pro-inflammatory cytokines are involved in the
induction of B1R and that TRPV1 is associated with pain
neuropathy, this series of experiments was carried out to
measure their expression in STZ-diabetic rats. As illus-
t ra t ed in T a ble  2,  m RNA leve ls o f  t hese  m a r k er s  we r e
Figure 2 Time-course effect of B1R antagonists administered in the periphery (A) or intrathecally (B) on blood glucose concentration in 
control and 4-day STZ-diabetic rats. Data are the mean ± S.E.M. of 5 rats in each group. Statistical comparison to control (*) or untreated (0 h) STZ-
treated rats (+) is indicated by + P < 0.05, ***P < 0.001.Talbot et al. Journal of Neuroinflammation 2010, 7:36
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markedly increased (IL-1β > B1R > TNF-α > TRPV1) in
the spinal cord of STZ-diabetic rats. Treatment with flu-
orocitrate (1 nmol, i.t.) or minocycline (10 mg/kg, i.p.), 3
h earlier, markedly reduced the enhanced mRNA to val-
ues not significantly different from control levels.
Effect of fluorocitrate on B1R specific binding sites in STZ 
thoracic spinal cord
A low density of specific kinin B1R binding sites was
detected in the spinal cord dorsal horn (laminae I-III) of
control rats (0.637 fmol/mg protein). This value was
increased by 4-fold in spinal cord of STZ-treated rats
(2.474 fmol/mg protein). Fluorocitrate (1 nmol, i.t.)
administered in STZ-diabetic rats, 3 h prior sacrifice,
reduced (-38%) the increased density of specific B1R
binding sites induced by diabetes to values (1.532 fmol/
mg protein) not significantly different from control den-
sity (Figure 4).
Effect of microglia inhibitors on thermal hyperalgesia 
mediated by des-Arg9-BK
As shown in Figure 5, control rats treated with SP (6.6
nmol, i.t.) showed a significant decrease in reaction time
to thermal stimulation at 1 min post-injection (-35%) in
comparison with aCSF. This response was not signifi-
cantly increased (-40%) in STZ-diabetic rats. Whereas
des-Arg9-BK (9.6 nmol, i.t.) had no significant effect in
control rats, a significant decrease in reaction time (-30%)
occurred at 1 min post-injection in STZ-diabetic rats. A 3
h pre-treatment with fluorocitrate (1 nmol, i.t.) or mino-
cycline (10 mg/kg, i.p.) abolished the hyperalgesic
response to des-Arg9-BK (-5% and + 2%, respectively).
Both fluorocitrate and minocycline reduced significantly
SP-induced hyperalgesia in STZ-diabetic rats. This result
indicates that microglia inhibition may partly contribute
to SP-induced hyperalgesia in STZ-diabetic rats. Baseline
values of the thermal nociceptive threshold in control rats
(9.04 ± 0.79; n = 5) were not affected (P > 0.05) at this
early stage of STZ-induced diabetes (9.16 ± 0.45; n = 5)
neither by fluorocitrate (9.07 ± 0.93; n = 5) nor minocy-
cline (9.12 ± 0.73; n = 5) treatment.
Effect of microglia inhibitors and B1R antagonists on 
allodynia induced by STZ
STZ-diabetic rats presented significant tactile (Figures 6,
7) and cold allodynia (Figures 8,9) in comparison with
Figure 3 Effect of microglia inhibitors administered 3 h earlier on Iba-1 microglial immunoreactivity in the spinal dorsal horn of control and 
4-day STZ-diabetic rats. Shown are (A) confocal microscopy pictures of microglial cells, and (B) the quantification of the mean pixel energy of Iba-1 
(in arbitrary unit, AU). Scale bar = 100 μm. Data are the mean ± S.E.M of 4 pictures per rat from 4 rats in each group. Background mean energy was 
subtracted for each picture. Statistical comparison to control (*) or STZ rats treated with vehicle (+) is indicated by *** +++ P < 0.001.Talbot et al. Journal of Neuroinflammation 2010, 7:36
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vehicle-matched control rats. These responses were sta-
ble when the tests were performed over a period of 24 h.
The B1R antagonists, SSR240612 and R-715, adminis-
tered systemically blocked in a transient and reversible
manner cold and tactile allodynia between 3 and 6 h post-
treatment in STZ-diabetic rats. Intrathecal treatments
with B1R antagonists provided more rapid and shorter
inhibition of allodynia (1-3 h) than systemic treatments
(3-6 h). Fluorocitrate and minocycline caused a similar
pattern of inhibition on tactile allodynia at 1 and 3 h post-
treatment while the inhibition of cold allodynia with
microglia inhibitors lasted at least up to 6 h post-treat-
Table 2: Gene expression of various markers in thoracic spinal cord of STZ-diabetic rats
gene mRNA/18S mRNA (fold change)
B1R TRPV1 IL-1β TNF-α
Control 1.0 ± 0.4 1.0 ± 0.1 1.0 ± 0.6 1.0 ± 0.6
STZ 27.3 ± 8.7 * 3.1 ± 0.4 * 77.9 ± 19.6 * 6.0 ± 2.1 **
STZ + Fluorocitrate 2.7 ± 1.1 2.3 ± 0.3 + 10.1 ± 7.9 0.9 ± 0.4 +
STZ + Minocycline 3.0 ± 1.3 2.6 ± 0.2 + 8.9 ± 4.2 2.1 ± 0.7 +
Effect of a 3 h pre-treatment with fluorocitrate (1 nmol, i.t.) or minocycline (10 mg/kg, i.p.) on gene expression of inflammatory markers in 
thoracic spinal cord of STZ-diabetic rats. Data represent the mean ± S.E.M. of 5-6 rats in each group. Statistical comparison to control (*) and 
STZ-diabetic rats without microglia inhibitors (+) is indicated by * + P < 0.05; **P < 0.01.
Figure 4 Effect of microglia inhibitors administered 3 h earlier on B1R binding sites in the thoracic spinal cord of control and 4-day STZ-
diabetic rats. Shown in (A) are autoradiograms of Control (I), Non-specific (II), STZ (III) and STZ + fluorocitrate (IV), and in (B) are the quantification of 
specific densities of B1R binding sites in spinal dorsal horn (Laminae I-III). Data are the mean ± S.E.M. of 5 to 6 rats in each group. Statistical comparison 
to control rats is indicated by **P < 0.01.Talbot et al. Journal of Neuroinflammation 2010, 7:36
http://www.jneuroinflammation.com/content/7/1/36
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ment. The same treatments with B1R antagonists or
microglia inhibitors had no consequence on baseline val-
ues in control rats.
Effect of microglia inhibitors on enhanced tactile allodynia 
induced by des-Arg9-BK in STZ-treated rats
As observed in Table 3, STZ-diabetic rats displayed sig-
nificant tactile allodynia in comparison with control rats.
In diabetic rats, the intrathecal stimulation of B1R with its
native agonist (des-Arg9-BK, 9.6 nmol) induced a signifi-
cant and transient enhancement of tactile allodynia at 10
min post-injection. This response was prevented by the
inhibition of B1R (SSR240612, 10 μg, i.t.) and of microglia
with fluorocitrate (1 nmol, i.t.) or minocycline (10 mg/kg,
i.p.) injected 3 h earlier. Those treatments administered
to control animals were without effect while they
reversed tactile allodynia in STZ-diabetic rats.
Discussion
The present findings support a primary role for spinal
microglial kinin B1R in early pain neuropathy in a rat
model of type 1 diabetes. Our study provides the first
direct evidence that the B1R is involved in allodynia and
hyperalgesia in STZ-diabetic rats through a mechanism
involving the microglia. This is supported by 1- the simi-
lar pattern of inhibition of allodynia by microglia inhibi-
tors and B1R antagonists, and 2- the blockade of the
transient allodynic and hyperalgesic responses induced
by the stimulation of spinal B1R (des-Arg9-BK) by micro-
glia inhibitors. Because spontaneous cold and tactile allo-
dynia in STZ-diabetic rats were reversed by intrathecal
B1R antagonists and by peripheral administration of R-
715, which does not cross the blood brain barrier, it is
concluded that both spinal and peripheral B1R are
involved in diabetic allodynia. This is consistent with the
presence of B1R on spinal dorsal horn microglia in STZ-
diabetic rats [22]. An additional argument supporting an
interaction between B1R and microglia is the finding that
fluorocitrate and minocycline reversed simultaneously
the upregulation of B1R and pro-inflammatory cytokines
(IL-1β and TNF-α) in the spinal cord. Hence, the results
highlight a key role for microglia and pro-inflammatory
cytokines in the induction and overexpression of B1R in
the spinal cord.
Validation of microglia inhibitors
Immunolabelling of Iba-1 in STZ-diabetic rats treated
with minocyline and fluorocitrate confirmed the inhibi-
tion of microglia. The Iba-1 immunolabelling in the spi-
nal dorsal horn of 4-days STZ-diabetic rats showed the
characteristics of activated microglia with larger cell
body, shorter and stouter processes [43,44]. In contrast,
Figure 5 Effect of microglia inhibitors administered 3 h earlier on tail-flick reaction time (MPE %) in control and 4-day STZ-diabetic rats. 
Shown are the maximal responses measured 1 min after intrathecal injection of either aCSF, 9.6 nmol des-Arg9-BK or 6.6 nmol SP. Data are the mean 
± S.E.M. of 5 rats in each group. Within groups, statistical comparison to aCSF is indicated by ††P < 0.01, while statistical comparison to the same agonist 
in the control group (*) or in STZ + vehicle (+) is indicated by * + P < 0.05; ++ ††P < 0.01; ***P < 0.001.Talbot et al. Journal of Neuroinflammation 2010, 7:36
http://www.jneuroinflammation.com/content/7/1/36
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resting-state microglia with small size cytoplasm and
long processes are observed in control spinal cord
[43,44]. As expected, microglia inhibitors caused a
marked diminution of Iba-1 immunoreativity and cell
body volume. This result is in accordance with the litera-
ture showing that minocycline caused a marked reduc-
tion of Iba-1 immunoreactivity in diabetes [28]. To the
best of our knowledge, this is however the first report
showing a decrease of Iba-1 immunoreactivity after flu-
orocitrate treatment.
B1R induction mechanism
W e observed an upregulation of both B1R binding sites
and mRNA in the spinal cord of STZ-diabetic rats in
comparison with its low level of expression in controls.
Those results are in accordance with previous studies
[22,23]. Hyperglycemia associated with type 1 diabetes
can activate NF-κB [45], which is known to induce B1R
[9,10]. Moreover, oxidative stress associated with diabetes
was reported to be involved in the induction of B1R
[19,46].
We demonstrated that microglia inhibition prevented
STZ-induced upregulation of B1R, TNF-α and IL-1β
mRNA. The microglia can release pro-inflammatory
mediators such as IL-1β [47], TNF-α [48] and reactive
oxygen species (ROS) [49] all known to induce B1R
through the nuclear translocation of NF-κB and the acti-
vation of its promoter [7,9,10]. Therefore, the suppres-
sion of B1R expression by fluorocitrate and minocycline is
most likely linked to the inhibition of pro-inflammatory
cytokines and ROS released from microglia. Since
TRPV1 activation can also contribute to B1R induction
[50], one cannot exclude that the inhibitory effect of
microglia inhibitors on B1R  i s  p a r t l y  m e d i a t e d  b y  t h e
inhibition of TRPV1 overexpression observed in STZ.
However, the increased mRNA level of TRPV1 in STZ
was much less striking (3-fold) than that of B1R (27-fold),
IL-1β (78-fold) and TNF-α (6-fold). The inhibitory effect
of fluorocitrate and minocycline on STZ-induced
increase of TRPV1 mRNA was also quite modest.
B1R spinal cord localization
A 3 h treatment with fluorocitrate normalized B1R
mRNA level, yet specific dorsal horn B1R binding sites
were reduced by only 38% in the spinal cord of STZ rats.
Figure 6 Time-course of the inhibitory effect of B1R antagonists administered in the periphery (A, C) or intrathecally (B, D) on spontaneous 
paw withdrawal threshold to tactile stimulation (g) in control and 4-day STZ-diabetic rats. All treatments were given at time 0 h. Data are the 
mean ± S.E.M. of 4 to 12 rats in each group. Statistical comparison to control + vehicle (*) and STZ + vehicle (+) is indicated by ++P < 0.01; *** +++P < 
0.001.Talbot et al. Journal of Neuroinflammation 2010, 7:36
http://www.jneuroinflammation.com/content/7/1/36
Page 11 of 16
This may suggest that the majority of induced and up-
regulated B1R mRNA is associated with microglial cells.
The discrepancy between mRNA and binding sites sug-
gests that about 62% of specific B1R binding sites origi-
n a t e  f r o m  o u t s i d e  t h e  s p i n a l  c o r d  s u c h  a s  d o r s a l  r o o t
ganglion cells projecting to the dorsal horn. This would
be  c o n s i s t e n t  wi t h  t h e  p r e s e n c e  o f  B 1R on sensory C-
fibers identified with CGRP and TRPV1 specific antibod-
Figure 7 Time-course of the inhibitory effect of fluorocitrate (A) and minocycline (B) on spontaneous paw withdrawal threshold to tactile 
stimulation (g) in control and 4-day STZ-diabetic rats. All treatments were given at time 0 h. Data are the mean ± S.E.M. of 4 rats in each group. 
Statistical comparison to control + vehicle (*) and STZ + vehicle (+) is indicated by *** +++P < 0.001.Talbot et al. Journal of Neuroinflammation 2010, 7:36
http://www.jneuroinflammation.com/content/7/1/36
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ies [22]. B1R binding sites may also represent receptors
located on bulbospinal projecting fibers and/or astro-
cytes. Based on this reasoning, data with fluorocitrate
suggest that microglial cells bear approximately 38% of all
B1R measured in the spinal cord of STZ-diabetic rats by
autoradiography. The present study does not exclude a
role for B1R present on sensory C-fibers and astrocytes in
allodynia and thermal hyperalgesia as these spinal cord
elements may interact with microglia to contribute to
neuropathic pain.
Allodynia
As early as 4 days after STZ-treatment, rats exerted sig-
nificant spontaneous cold and tactile allodynia compared
with control rats as already reported [28]. For the first
time, we demonstrated that acute blockade of spinal cord
B1R with SSR240612 or R-715 can reverse both types of
allodynia in STZ-diabetic rats. Our results also showed
that systemic blockade of B1R with the peptide B1R antag-
onist R-715 reversed STZ-induced allodynia, supporting
the idea that peripherally expressed B1R may also con-
tribute to neuropathic pain. This is in keeping with our
recent results showing that tactile and cold allodynia,
observed in a rat model of insulin resistance [20,21], can
be prevented with either peripherally or centrally acting
B1R antagonists.
Although it was extensively studied, the exact mecha-
nism underlying sensory abnormalities in STZ-treated
rats remained unclear [51]. Recent literature suggests that
spinal dorsal horn microglia is a crucial component of
STZ-induced tactile allodynia which is partly mediated
by the extracellular signal-regulated protein kinase sig-
naling [28]. Moreover, studies have implicated the activa-
tion of stress-activated mitogen-activated protein kinase
(MAPK) p38 in spinal microglial cells in the rat model of
plantar incision-induced mechanical allodynia [52]. Inhi-
bition of microglia activation with Gabapentin [25] or flu-
orocitrate and minocycline (present study) reversed
Figure 8 Time-course of the inhibitory effect of B1R antagonists administered in the periphery (A, C) or intrathecally (B, D) on paw with-
drawal response frequency (%) to cold stimulation in control and 4-day STZ-diabetic rats. All treatments were given at time 0 h. Data represent 
the mean ± S.E.M. of 4 to 12 rats in each group. Statistical comparison to control + vehicle (*) and STZ + vehicle (+) is indicated by ++P < 0.01; *** +++P 
< 0.001.Talbot et al. Journal of Neuroinflammation 2010, 7:36
http://www.jneuroinflammation.com/content/7/1/36
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Figure 9 Time-course of the inhibitory effect of fluorocitrate (A) and minocycline (B) on paw withdrawal response frequency (%) to cold 
stimulation in control and 4-day STZ-diabetic rats. All treatments were given at time 0 h. Data are the mean ± S.E.M. of 4 rats in each group. Sta-
tistical comparison to control + vehicle (*) and STZ + vehicle (+) is indicated by ++P < 0.01; +++ ***P < 0.001.Talbot et al. Journal of Neuroinflammation 2010, 7:36
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allodynia in STZ-treated rats. This is the first report
showing the anti-neuropathic potential of minocyline in
diabetic rats. The anti-allodynic effect of minocyline in
rats was reported in the formalin test [53] and in neuro-
pathic pain models of sciatic or spinal nerve injury [54-
56]. Likewise, fluorocitrate could reverse allodynia in var-
ious models of polyneuropathy, including that induced by
sciatic nerve injury [41], intrathecal ATP [40] and intrath-
ecal HIV-1 envelope glycoprotein gp120 [57]. Thus, this
is also the first demonstration that fluorocitrate can
reverse diabetic allodynia.
Allodynia induced by spinal cord B1R stimulation
Importantly, this study presented the first evidence that
spinal cord activation of B1R with its native agonist
enhanced tactile allodynia in STZ-diabetic rats. This
effect was prevented by a pre-treatment with an antago-
nist of B1R or by microglia inhibition, providing a strong
argument that the allodynic response does involve micro-
glial B1R. This is in accordance with the pro-nociceptive
role of many other G-protein coupled-receptors
expressed on microglia, including TLR2-4, P2Y12R,
CCR2, CX3CR1 [58].
Hyperalgesia mediated by the B1R
The activation of spinal cord tachykinin NK-1 receptor
with SP caused a hyperalgesic response in the tail-flick
test, which was associated with the release of glutamate
and NO in control rats [42,59,60]. Whereas intrathecal
administration of des-Arg9-BK, the selective B1R agonist,
had no effect on the nociceptive threshold in control rats,
it evoked a transient hyperalgesia in STZ-diabetic rat,
which was likely mediated by the release of pro-inflam-
matory mediators (NO, SP and glutamate) based on phar-
macological blockade of NOS, NK-1R and NMDAR [7].
The present study extended this observation by demon-
strating that thermal hyperalgesia elicited by the B1R ago-
nist in STZ-diabetic rats requires intact microglia. This is
consistent with the effects of pro-nociceptive mediators
such as NO [61], ROS [49], SP [62] and glutamate [63],
which can be released by microglia.
The therapeutic effects of B1R antagonists and micro-
glia inhibitors on allodynia and hyperalgesia are unlikely
due to changes in blood glucose concentrations since
microglia inhibitors and intrathecal B1R antagonist
reversed pain neuropathy without affecting hyperglyce-
mia in STZ-diabetic rats. Although SSR240612 reduced
Table 3: Effect of spinal cord B1R stimulation on tactile allodynia in STZ-diabetic rats
Tactile allodynia (g)
0 min 5 min 10 min 15 min 30 min 60 min
Control rats
Vehicle 9.7 ± 0.3 9.7 ± 0.3 9.3 ± 0.7 9.7 ± 0.3 9.7 ± 0.3 9.7 ± 0.3
DABK (9.6 nmol, i.t.) 9.7 ± 0.3 9.7 ± 0.3 9.3 ± 0.7 9.7 ± 0.3 9.7 ± 0.3 9.7 ± 0.3
SSR240612 (10 μg, i.t.) + DABK 10.7 ± 0.3 9.7 ± 0.3 9.3 ± 0.7 9.7 ± 0.3 9.7 ± 0.3 9.7 ± 1.3
FLU (1 nmol, i.t.) + DABK 9.7 ± 0.3 9.7 ± 0.3 9.3 ± 0.7 9.7 ± 0.3 9.7 ± 0.3 9.7 ± 0.3
Mino (10 mg/kg, i.p.) + DABK 9.7 ± 0.3 9.7 ± 0.3 9.3 ± 0.7 9.7 ± 0.3 9.7 ± 0.3 9.7 ± 0.3
Tactile allodynia (g)
0 min 5 min 10 min 15 min 30 min 60 min
STZ-treated rats
Vehicle 6.3 ± 0.3*** 6.0 ± 0.5*** 6.3 ± 0.3*** 6.3 ± 0.3*** 6.3 ± 0.3*** 6.0 ± 0.5***
DABK (9.6 nmol, i.t.) 6.0 ± 0.5*** 5.3 ± 0.4*** 4.3 ± 0.3++ *** 5.3 ± 0.4*** 6.0 ± 0.0*** 5.7 ± 0.3***
SSR240612 (10 μg, i.t.) + DABK 9.3 ± 0.3+++ 9.3 ± 0.0+++ 9.3 ± 0.0+++ 9.3 ± 0.3+++ 9.7 ± 0.3+++ 9.3 ± 0.0+++
FLU (1 nmol, i.t.) + DABK 9.7 ± 0.3+++ 9.7 ± 0.3+++ 9.7 ± 0.3+++ 9.7 ± 0.3+++ 9.3 ± 0.4+++ 9.3 ± 0.4+++
Mino (10 mg/kg, i.p.) + DABK 9.7 ± 0.3+++ 9.0 ± 0.4+++ 9.3 ± 0.4+++ 9.3 ± 0.4+++ 8.7 ± 0.4+++ 9.3 ± 0.4+++
Time-course effect of a single intrathecal (i.t.) injection of the B1R agonist, des-Arg9-BK (DABK, 9.6 nmol), on the paw withdrawal threshold to 
tactile stimulation (g) in control and 4-day STZ-diabetic rats pre-treated, 3 h earlier, with either B1R antagonist (SSR240612), microglia inhibitors 
(minocycline, fluorocitrate) or vehicle. Data represent the mean ± S.E.M. of 4 to 12 rats in each group. Statistical comparison to vehicle in control 
(*) and STZ-treated rats (+) is indicated by ++P < 0.01; *** +++P < 0.001Talbot et al. Journal of Neuroinflammation 2010, 7:36
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significantly hyperglycemia at 3 h post-gavage, rats
remained diabetics (glycemia > 18 mmol/L). The mecha-
nism of the transient anti-hyperglycemic effect of
SSR240612 could be attributed to the inhibition of islet
inflammation (insulitis) as suggested earlier in studies
using [Leu8]des-Arg9-BK as B1R antagonist in STZ-dia-
betic mice [64,65].
Conclusion
This study provides the first pharmacological evidence
that spinal dorsal horn microglial B1R contributes to early
pain neuropathy in a rat model of type 1 diabetes. Micro-
glial B1R induction could be related to the production and
release of spinal pro-inflammatory cytokines such as IL-
1β and TNF-α. Hence, microglial B 1R may represent a
promising therapeutic target for the treatment of diabetic
pain neuropathy.
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